XML 41 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net loss $ (19,375) $ (11,168) $ (8,735)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation expense 338 145 41
Amortization of intangible assets 242 242 242
Stock-based compensation 1,630 922 1,815
Loss on sale of available-for-sale securities, including selling commissions 309 0 0
Warrants issued to certain shareholders as inducement to exercise of warrants 4,074 0 0
Contingently issuable warrant expense to investors 0 0 65
Amortization of debt issuance costs and interest expense 83 0 18
Changes in operating assets and liabilities:      
Amount due to BioTime and affiliates (753) 2,007 1,557
Prepaid expenses and other current assets 115 101 (274)
Accounts payable and accrued liabilities (48) 229 1,042
Net cash used in operating activities (13,385) (7,522) (4,229)
CASH FLOWS FROM INVESTING ACTIVITIES:      
Net proceeds from sale of available-for-sale securities 934 0 815
Purchase of equipment (91) (106) (500)
Security deposit 0 (75) 0
Net cash provided by (used in) investing activities 843 (181) 315
CASH FLOWS FROM FINANCING ACTIVITIES:      
Proceeds from exercise of options 610 218 4
Proceeds from exercise of warrants 7,774 0 0
Proceeds from sale of common stock 0 0 11,649
Proceeds from sale of common stock and warrants 0 10,550 0
Financing costs related to sale of common stock and warrants 0 (773) 0
Proceeds from issuance of loan payable, net of financing costs 1,982 0 0
Repayment of loan payable (133) 0 0
Repayment of capital lease obligation (265) (114) 0
Net cash provided by financing activities 9,968 9,881 11,653
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (2,574) 2,178 7,739
CASH AND CASH EQUIVALENTS:      
At beginning of the year 10,174 7,996 257
At end of the year 7,600 10,174 7,996
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION      
Cash paid for interest 130 29 0
SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES      
Equipment purchased under capital leases 381 626 0
Debt issuance costs 196 0 0
Common stock issued to BioTime for extinguishment of debt 0 0 3,300
Common stock issued to BioTime upon conversion of convertible note payable and accrued interest 0 0 3,318
Realized loss on sale of BioTime shares $ 0 $ 0 $ 397